Page 19 - 南京医科大学学报自然科学版
P. 19
第43卷第5期 刘思远,陈 琳,夏安亮,等. 嵌合抗原受体NK细胞治疗肝细胞癌的研究进展[J].
2023年5月 南京医科大学学报(自然科学版),2023,43(5):595-603,647 ·601 ·
久的反应性,且未见严重不良反应。 [6] EL⁃KHOUEIRY A B,SANGRO B,YAU T,et al. Nivolum⁃
综上,将抗 NKG2A 的免疫检查点抑制剂和 ab in patients with advanced hepatocellular carcinoma
CAR⁃NK 细胞联合治疗 HCC,既可以精准、快速、高 (CheckMate 040):an open ⁃ label,non ⁃ comparative,
phase 1/2 dose escalation and expansion trial[J]. Lancet,
效地靶向肿瘤,又可以克服 HLA⁃E 介导的肿瘤对
2017,389(10088):2492-2502
NK细胞的抵抗,提高CAR⁃NK的功能。目前这一思
[7] ZHU A X,FINN R S,EDELINE J,et al. Pembrolizumab
路正得到越来越多的关注,作为第一代抗癌免疫疗
in patients with advanced hepatocellular carcinoma previ⁃
法的补充,有望在将来HCC的基础研究和临床治疗
ously treated with sorafenib(KEYNOTE⁃224):a non⁃ran⁃
中展现进一步效果。 domised,open ⁃ label phase 2 trial[J]. Lancet Oncol,
5 小结与展望 2018,19(7):940-952
[8] SOVE R J,VERMA B K,WANG H,et al. Virtual clinical
CAR⁃NK细胞疗法凭借其出色的安全性和确切 trials of anti⁃PD⁃1 and anti⁃CTLA⁃4 immunotherapy in ad⁃
的疗效成为了肝癌免疫治疗领域的一颗新星,近年 vanced hepatocellular carcinoma using a quantitative sys⁃
来针对不同靶点的CAR⁃NK细胞的临床前研究都显 tems pharmacology model[J]. J Immunother Cancer,
示出了良好的抗肿瘤效果,与 ICI 的联合应用也体 2022,10(11):e005414
[9] SCHULZ T U,ZIEROLD S,SACHSE M M,et al. Persis⁃
现出了强大的抗癌活性。但无法回避的是,若想实
tent immune ⁃ related adverse events after cessation of
现肝癌的可靠治愈,CAR⁃NK 还需克服诸多挑战。
checkpoint inhibitor therapy:prevalence and impact on
未来CAR⁃NK 需要持续优化CAR的设计,以期获得 patients’health⁃related quality of life[J]. Eur J Cancer,
更好的特异性、更强的细胞毒性和更高的安全性。
2022,176:88-99
此外,如何逆转不断变化的肿瘤微环境对 NK 细胞 [10] ELSALLAB M,LEVINE B L,WAYNE A S,et al. CAR T⁃
的抑制,恢复NK细胞的功能以增强CAR⁃NK的抗癌 cell product performance in haematological malignancies
效果更是任重而道远的课题。欣喜的是,目前有很 before and after marketing authorisation[J]. Lancet On⁃
多 CAR⁃NK 的基础研究和临床试验正在积极推进, col,2020,21(2):e104-e116
而随着这些难题被不断突破,相信将来 CAR⁃NK 会 [11] YOSHIDA Y,YOSHIO S,YAMAZOE T,et al. Phenotyp⁃
ic characterization by single ⁃ cell mass cytometry of hu⁃
在肝癌的免疫治疗中获得更广阔的应用前景。
man intrahepatic and peripheral NK cells in patients with
[参考文献] hepatocellular carcinoma[J]. Cells,2021,10(6):1495
[1] SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer [12] LI C,WEI S,XU X,et al. Sorafenib attenuated the func⁃
statistics 2020:GLOBOCAN estimates of incidence and tion of natural killer cells infiltrated in HCC through in⁃
mortality worldwide for 36 cancers in 185 countries[J]. hibiting ERK1/2[J]. Int Immunopharmacol,2019,76:
CA Cancer J Clin,2021,71(3):209-249 105855
[2] XU F,MENG Q,WU F,et al. Identification of warning [13] MAHGOUB S,ABOSALEM H,EMARA M,et al. Restor⁃
transition points from hepatitis B to hepatocellular carci⁃ ing NK cells functionality via cytokine activation enhanc⁃
noma based on mutation accumulation for the early diag⁃ es cetuximab⁃mediated NK⁃cell ADCC:a promising thera⁃
nosis and potential drug treatment of HBV⁃HCC[J]. Oxid peutic tool for HCC patients[J]. Mol Immunol,2021,
Med Cell Longev,2022,2022:3472179 137:221-227
[3] VOGEL A,MEYER T,SAPISOCHIN G,et al. Hepatocel⁃ [14] LIU Z,YOU Y,CHEN Q,et al. Extracellular vesicle⁃me⁃
lular carcinoma[J]. Lancet,2022,400(10360):1345 ⁃ diated communication between hepatocytes and natural
1362 killer cells promotes hepatocellular tumorigenesis[J].
[4] LIU Y,WANG Z X,CAO Y,et al. Preoperative inflamma⁃ Mol Ther,2022,30(2):606-620
tion ⁃ based markers predict early and late recurrence of [15] ZERBINI A,PILLI M,LACCABUE D,et al. Radiofre⁃
hepatocellular carcinoma after curative hepatectomy[J]. quency thermal ablation for hepatocellular carcinoma
Hepatobiliary Pancreat Dis Int,2016,15(3):266-274 stimulates autologous NK⁃cell response[J]. Gastroenterol⁃
[5] KUDO M,FINN R S,QIN S,et al. Lenvatinib versus ogy,2010,138(5):1931-1942
sorafenib in first⁃line treatment of patients with unresect⁃ [16] HUANG W,CHEN Q,DAI J,et al. miR⁃744⁃5p suppress⁃
able hepatocellular carcinoma:a randomised phase 3 non⁃ es tumor proliferation and metastasis by targeting trans⁃
inferiority trial[J]. Lancet,2018,391(10126):1163- forming growth factor⁃beta 1(TGF⁃beta1)in hepatocellu⁃
1173 lar carcinoma(HCC)[J]. J Gastrointest Oncol,2021,12